Apexigen
Signal active
Organization
Contact Information
Overview
Apexigen is a clinical-stage biopharmaceutical company developing antibody therapeutics for the treatment of cancer. It specializes in new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer.
About
Industries
Biotechnology, Health Care, Pharmaceutical, Biopharma, Oncology
Founded
2010
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Apexigen headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Biopharma, Oncology sector. The company focuses on Biotechnology and has secured $21.1B in funding across 120 round(s). With a team of 11-50 employees, Apexigen is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Apexigen, raised $20.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
6
Investors
5
Lead Investors
0
Total Funding Amount
$175.8M
Details
4
Apexigen has raised a total of $175.8M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2018 | Early Stage Venture | 15.0M | ||
| 2018 | Late Stage Venture | 58.0M | ||
| 2020 | Late Stage Venture | 65.0M | ||
| 2013 | Early Stage Venture | 20.0M |
Investors
Apexigen is funded by 14 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Virtus Inspire Ventures | - | FUNDING ROUND - Virtus Inspire Ventures | 65.0M |
| Karen Liu | - | FUNDING ROUND - Karen Liu | 65.0M |
| 3E Bioventures | - | FUNDING ROUND - 3E Bioventures | 65.0M |
| Apexigen | - | FUNDING ROUND - Apexigen | 65.0M |
Recent Activity
There is no recent news or activity for this profile.